Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study

Summary

The purpose of this study is to evaluate the efficacy and safety of rivaroxaban for the prevention of deep vein thrombosis in patients with left iliac vein compression treated with stent implantation.

Conditions

• May-Thurner Syndrome

Interventions

DRUG

Rivaroxaban

Dose: 15mg twice daily for three weeks, then 20mg once daily until six months after the operation. Application: oral

DRUG

Warfarin

Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral

DRUG

Nadroparin

Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous

Sponsors & Collaborators

• Sir Run Run Shaw Hospital

  collaborator OTHER

• Huadong Hospital

  collaborator OTHER

• Shanghai Zhongshan Hospital

  collaborator OTHER

• Shanghai 5th People's Hospital

  collaborator OTHER

• Yantai Yuhuangding Hospital

  collaborator OTHER

• Anhui Provincial Hospital

  collaborator OTHER_GOV

• Zhejiang Provincial People's Hospital

  collaborator OTHER

• Zhejiang Hospital

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  lead OTHER

Principal Investigators

• Zhejie Liu, MD,PhD · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-05-18

Primary Completion

2024-12-31

Completion

2024-12-31

Countries

• China

Study Locations